Boehringer Ingelheim launches three phase III trials in precision Oncology
Boehringer Ingelheim has initiated three Phase III clinical trials aimed at advancing…
Global Survey Reveals Gaps in Pet Parasite Awareness as Prevention Efforts Urged
A global survey released for World Parasite Awareness Day highlights gaps in…
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO®
Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and…
Compliance Officer, Boehringer Ingelheim IMETA (India, Middle East, Turkey, Africa)
Hani Hussein is a seasoned compliance leader with over 25 years of…
DoH and Boehringer Ingelheim Ink Strategic Partnership to Advance Life Science Innovation Across the Emirate
The Department of Health – Abu Dhabi (DoH), the regulator of the…
Boehringer Ingelheim and VSF Germany unite to fight Rabies in Kenya
Ingelheim- December 2024- Having recently signed an agreement to fight rabies in…
Ministry of Health Saudi Arabia and Boehringer Ingelheim Unite for Better Stroke Care
Riyadh, Kingdom of Saudi Arabia- November 2024- Boehringer Ingelheim has signed a…
Boehringer Ingelheim to submit nerandomilast for IPF treatment approval
Ingelheim, Germany- September 2024- Boehringer Ingelheim announced that the FIBRONEER™-IPF trial met…
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments
Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global…
